CorAlert (קוראלרט)

Beersheba, Israel

CorAlert is developing a noninvasive device for the early detection and monitoring of heart failure in real time. Suitable for both inpatient and outpatient environments, the device accurately estimates left ventricular end-diastolic pressure (LVEDP) by analyzing central aortic pressure derived from measurements of pressure at the brachial artery and timing measurements based on heartbeat sounds. The CorAlert device provides a comprehensive hemodynamic picture that includes the rate of pressure increase in the aorta during ejection (dP/dt) and an index correlated to systemic vascular resistance (SVR). The comprehensive hemodynamic profile supplied by the device enables the physician to accurately determine each patient's precise condition and type of dysfunction. The company's solution was validated in 10 patients in a clinical trial conducted at Ziv Medical Center in Israel using CorAlert's alpha model. CorAlert has completed production of its beta model, which has commenced a clinical trial in Israel.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out CorAlert (קוראלרט) on @MedStartr Today #HeartFailure #CongestiveHeartFailureCHF #CardiovascularDisease #CardiacDiseases #Prevention #MedMo #MedStartrVentures

https://www.medstartr.ai/s/lB9U5ieDdKw

Get Involved in CorAlert (קוראלרט)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2012
Website: www.coralert.com

Disease Areas

Heart Failure Congestive Heart Failure (CHF)Cardiovascular Disease Cardiac Diseases

Technologies

Medical DevicesNon-Invasive DiagnosticsPhysiological Monitoring

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of CorAlert (קוראלרט)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.